🔥🐔 BizChicken 🐔🔥

Companies Similar to Corcept Therapeutics Incorporated

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

CAP-1002

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing transformative cell and exosome-based therapeutics aimed at treating and preventing a range of diseases and disorders. Their lead candidate, CAP-1002, is designed for Duchenne muscular dystrophy and cytokine storm interventions.

Tags: COVID-19, Duchenne muscular dystrophy, biotechnology, cell therapy, therapeutics

Symbol: CAPR

Recent Price: $13.76

Industry: Biotechnology

CEO: Dr. Linda Marbán Ph.D.

Sector: Healthcare

Employees: 101

Address: 10865 Road to the Cure, San Diego, CA 92121

Phone: 310 358 3200

Leadership

  • Linda Marbán, Ph.D., Chief Executive Officer and Director
  • Kristi A. H. Elliott, Ph.D., Chief Science Officer
  • AJ Bergmann, M.B.A., Chief Financial Officer
  • Karen G. Krasney, J.D., Executive Vice President and General Counsel
  • Mark Awadalla, Vice President of Clinical Operations
  • Jonathan Tayco, Vice President of Program Management and Business Operations
  • Minghao Sun, Ph.D., Vice President of Research and Product Development
  • Yushi Feng, Ph.D., Vice President of Regulatory Affairs
  • Frank Litvack M.D., FACC, Executive Chairman
  • Paul G. Auwaerter, M.D., M.B.A., FIDSA, Director
  • Earl M. (Duke) Collier Jr., Director
  • George W. Dunbar, Jr., Director
  • Philip J. Gotwals, Ph.D., Director
  • Michael Kelliher, Director
  • David B. Musket, Director
  • Karimah Es Sabar, Director

Last updated: 2024-12-31

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Firdapse

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuromuscular and neurological diseases in the United States, including products like Firdapse and Ruzurgi for Lambert-Eaton Myasthenic Syndrome.

Tags: Firdapse, Ruzurgi, biopharmaceutical, neurological diseases, neuromuscular diseases, rare diseases

Symbol: CPRX

Recent Price: $21.07

Industry: Biotechnology

CEO: Mr. Richard John Daly M.B.A.

Sector: Healthcare

Employees: 167

Address: 355 Alhambra Circle, Coral Gables, FL 33134

Phone: 305 420 3200

Last updated: 2024-12-31

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

losmapimod and FTX-6058

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States.

Tags: FTX-6058, biopharmaceutical, clinical-stage, facioscapulohumeral muscular dystrophy, genetically defined diseases, hemoglobinopathies, losmapimod, sickle cell disease

Symbol: FULC

Recent Price: $4.68

Industry: Biotechnology

CEO: Mr. Alexander C. Sapir

Sector: Healthcare

Employees: 76

Address: 26 Landsdowne Street, Cambridge, MA 02139

Phone: 617 651 8851

Last updated: 2024-12-31

Omeros Corporation

Omeros Corporation logo
Market Cap: Low
Employees: Low

Narsoplimab

Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.

Tags: Narsoplimab, addiction, biopharmaceutical, clinical trials, drug development, immune system, therapeutics

Symbol: OMER

Recent Price: $9.74

Industry: Biotechnology

CEO: Dr. Gregory A. Demopulos M.D.

Sector: Healthcare

Employees: 198

Address: The Omeros Building, Seattle, WA 98119

Phone: 206 676 5000

Last updated: 2024-12-31

Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Highest

Emverm, Rytary, Unithroid

Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products across various dosage forms and therapeutic areas, operating through Generics, Specialty, and Av KARE segments.

Tags: Generics, Healthcare, Pharmaceuticals, Specialty, Therapeutics

Symbol: AMRX

Recent Price: $7.83

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Chirag K. Patel

Sector: Healthcare

Employees: 7850

Address: 400 Crossing Boulevard, Bridgewater, NJ 08807

Phone: 908 947 3120

Leadership

  • Chirag Patel, President and Co-Chief Executive Officer
  • Chintu Patel, Co-Chief Executive Officer
  • Tasos Konidaris, Executive Vice President, Chief Financial Officer
  • Nikita Shah, Executive Vice President, Chief Human Resources Officer
  • Jason B. Daly, Esq., Senior Vice President, Chief Legal Officer & Corporate Secretary
  • Gregory Sgammato, Senior Vice President, Corporate Development
  • Andrew S. Boyer, Executive Vice President, Chief Commercial Officer – Generics
  • Joe Renda, Senior Vice President, Chief Commercial Officer - Specialty
  • Shyamakant Giri, President, India Business & Emerging Markets
  • Sanjay Kumar Jain, PhD, Chief Quality Officer
  • Srinivas Kone, PhD, Senior Vice President, Chief Scientific Officer – Generics
  • Richard D’Souza, PhD, Senior Vice President, Specialty R&D
  • Maryll W. Toufanian, Senior Vice President, Regulatory Strategy and Government Affairs
  • Pranav Mehta, Senior Vice President, Strategic Sourcing & Supply Management
  • Sandeep R. Raktate, President, Operations – India & Ireland

Last updated: 2024-12-31

Ardelyx, Inc.

Ardelyx, Inc. logo
Market Cap: High
Employees: Low

tenapanor

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.

Tags: CKD, biopharmaceutical, cardiorenal, gastrointestinal, hyperkalemia, hyperphosphatemia, metabolic acidosis, tenapanor

Symbol: ARDX

Recent Price: $5.25

Industry: Biotechnology

CEO: Mr. Michael G. Raab

Sector: Healthcare

Employees: 267

Address: 400 Fifth Avenue, Waltham, MA 02451

Phone: 510 745 1700

Leadership

  • Justin Renz, Chief Financial & Operations Officer
  • Eric Foster, Chief Commercial Officer
  • Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
  • Laura Williams, MD MPH, Chief Medical Officer
  • Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
  • David Rosenbaum, PhD, Chief Development Officer
  • Mike Kelliher, Executive Vice President, Corporate Development and Strategy
  • Charon Spencer, Chief Human Resources Officer
  • David Mott, Chairman
  • Robert Bazemore, Director
  • William A. Bertrand, Jr., JD, Director
  • Muna Bhanji, R.Ph, Director
  • Onaiza Cadoret-Manier, Director
  • Mike Raab, Director
  • Richard Rodgers, Director

Last updated: 2024-12-31

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated logo
Market Cap: High
Employees: Medium

Korlym (mifepristone)

Corcept Therapeutics discovers, develops, and commercializes drugs for treating severe metabolic, oncologic, and neuropsychiatric disorders in the United States, including their product Korlym for Cushing's syndrome.

Tags: Cushing's syndrome, biotechnology, neuropsychiatric disorders, oncology, pharmaceuticals

Symbol: CORT

Recent Price: $50.85

Industry: Biotechnology

CEO: Dr. Joseph K. Belanoff M.D.

Sector: Healthcare

Employees: 352

Address: 149 Commonwealth Drive, Menlo Park, CA 94025

Phone: 650 327 3270

Last updated: 2024-12-31

Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. logo
Market Cap: Low
Employees: Lowest

lenabasum, CRB-601, CRB-602

Corbus Pharmaceuticals Holdings, Inc., is a biopharmaceutical company focused on immune modulators for immuno-oncology and fibrosis diseases, developing products like lenabasum and monoclonal antibodies for cancer and fibrosis.

Tags: biopharmaceutical, cancer treatment, cannabinoid receptors, fibrosis, immune modulators, immuno-oncology, metabolic disorders

Symbol: CRBP

Recent Price: $12.08

Industry: Biotechnology

CEO: Dr. Yuval Cohen Ph.D.

Sector: Healthcare

Employees: 19

Address: 500 River Ridge Drive, Norwood, MA 02062

Phone: 617 963 0100

Leadership

  • Alan Holmer, Chairman of the Board
  • Yuval Cohen, Ph.D., Chief Executive Officer, Director
  • Anne Altmeyer, Ph.D., Director
  • Yong Ben, M.D., MBA, Director
  • Rachelle Jacques, Director
  • John Jenkins, M.D., Director
  • Pete Salzmann, M.D., MBA, Director
  • Winston Kung, MBA, Director
  • Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer
  • Sean Moran, CPA, MBA, Chief Financial Officer
  • Christina Bertsch, VP of Human Resources
  • Dr. Dominic Smethurst, Chief Medical Officer

Last updated: 2024-12-31

Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Lowest

Mupadolimab (CPI-006)

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies, including Mupadolimab for non-small cell lung cancer, CPI-818 for T-cell lymphomas, and Ciforadenant for renal cell cancer.

Tags: biopharmaceutical, biotech, cancer therapy, clinical trials, immuno-oncology

Symbol: CRVS

Recent Price: $5.25

Industry: Biotechnology

CEO: Dr. Richard A. Miller M.D.

Sector: Healthcare

Employees: 28

Address: 863 Mitten Road, Burlingame, CA 94010

Phone: 650 900 4520

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • Hervé Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. logo
Market Cap: Low
Employees: Medium

XPOVIO

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.

Tags: SINE compounds, XPO1, cancer treatment, nuclear export, oncology, pharmaceutical

Symbol: KPTI

Recent Price: $0.70

Industry: Biotechnology

CEO: Mr. Richard A. Paulson M.B.A.

Sector: Healthcare

Employees: 325

Address: 85 Wells Avenue, Newton, MA 02459

Phone: 617 658 0600

Leadership

  • Richard Paulson, President and Chief Executive Officer
  • James Accumanno, Chief Compliance Officer
  • Brian Austad, Senior Vice President, Pharmaceutical Sciences
  • Sohanya Cheng, Chief Commercial Officer and Head of Business Development
  • Lisa DiPaolo, Chief Human Resources Officer
  • Mike Mano, Senior Vice President and General Counsel
  • Michael Mason, Chief Financial Officer
  • Stuart Poulton, Chief Development Officer
  • Reshma Rangwala, Chief Medical Officer & Head of Research
  • Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
  • Elhan Webb, Senior Vice President, Investor Relations
  • Garen Bohlin, Director
  • Barry E. Greene, Lead Director
  • Mansoor Raza Mirza, MD, Director
  • Richard Paulson, MBA, President and Chief Executive Officer
  • Christy J. Oliger, Director
  • Deepa R. Pakianathan, PhD, Director
  • Chen Schor, Director
  • Zhen Su, MD, MBA, Director

Last updated: 2024-12-31

Keros Therapeutics, Inc.

Keros Therapeutics, Inc. logo
Market Cap: High
Employees: Low

KER-050

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hematological and musculoskeletal disorders. Their lead product candidate, KER-050, targets cytopenias, including anemia and thrombocytopenia.

Tags: biopharmaceutical, clinical-stage, cytopenias, hematological disorders, musculoskeletal disorders

Symbol: KROS

Recent Price: $15.64

Industry: Biotechnology

CEO: Dr. Jasbir S. Seehra Ph.D.

Sector: Healthcare

Employees: 149

Address: 99 Hayden Avenue, Lexington, MA 02421

Phone: 617 314 6297

Leadership

  • Jasbir Seehra, Ph.D., Board Member
  • Keith Regnante, M.B.A., Chief Financial Officer
  • Christopher Rovaldi, President, Chief Operating Officer
  • Esther Cho, J.D., Senior Vice President, General Counsel
  • John Oram, M.B.A., Senior Vice President, Program and Portfolio Management
  • Robin Wagner, Senior Vice President, Human Resources
  • Carl L. Gordon, Ph.D., C.F.A., Board Member
  • Jean-Jacques Bienaimé, M.B.A., Lead Independent Director
  • Nima Farzan, M.B.A., Board Member
  • Mary Ann Gray, Ph.D., Board Member
  • Tomer Kariv, J.D., Board Member
  • Julius Knowles, M.B.A., Board Member
  • Ran Nussbaum, Board Member
  • Alpna Seth, Ph.D., Board Member

Last updated: 2024-12-31

Korro Bio, Inc.

Korro Bio, Inc. logo
Market Cap: Low
Employees: Low

genetic medicines based on editing RNA

Korro Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing genetic medicines based on RNA editing to treat rare and widespread diseases. The company is based in Cambridge, Massachusetts and aims to provide clinical benefits through their innovative approach.

Tags: AATD, RNA editing, SERPINA1, biopharmaceutical, genetic medicines, rare diseases

Symbol: KRRO

Recent Price: $38.11

Industry: Biotechnology

CEO: Mr. Ram Aiyar MBA, Ph.D.

Sector: Healthcare

Employees: 92

Address: One Kendall Square, Cambridge, MA 02139-1562

Phone: 781-315-4600

Last updated: 2024-12-31

Kura Oncology, Inc.

Kura Oncology, Inc. logo
Market Cap: High
Employees: Low

ziftomenib and tipifarnib

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for the treatment of cancer. It focuses on genetically defined subsets of acute leukemias and has a collaboration with Novartis for certain carcinoma treatments.

Tags: biopharmaceutical, cancer treatment, clinical trials, hematologic, leukemia, small molecule, solid tumors

Symbol: KURA

Recent Price: $8.51

Industry: Biotechnology

CEO: Dr. Troy Edward Wilson J.D., Ph.D.

Sector: Healthcare

Employees: 142

Address: 12730 High Bluff Drive, San Diego, CA 92130

Phone: 858 500 8800

Last updated: 2024-12-31

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. logo
Market Cap: High
Employees: Low

novel small molecule therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

Tags: IRAK4 program, autoimmune diseases, biopharmaceutical, immunology, inflammation, oncology, protein degradation, therapeutics

Symbol: KYMR

Recent Price: $39.32

Industry: Biotechnology

CEO: Dr. Nello Mainolfi M.D., Ph.D.

Sector: Healthcare

Employees: 184

Address: 200 Arsenal Yards Boulevard, Watertown, MA 02472

Phone: 857 285 5300

Leadership

  • Nello Mainolfi, Ph.D., Founder, President & CEO
  • Jeremy Chadwick, Ph.D., Chief Operating Officer
  • Ellen Chiniara, JD, Chief Legal Officer and Corporate Secretary
  • Jared Gollob, MD, Chief Medical Officer
  • Bruce Jacobs, CFA, MBA, Chief Financial Officer
  • Karen Weisbach, Head of People and Culture
  • Juliet Williams, Ph.D., Head of Research
  • Bruce Booth, DPhil, Chairman and Co-Founder
  • Felix J. Baker, PhD, Lead Independent Director
  • Jeff Albers, JD, MBA,
  • Pamela Esposito, PhD,
  • Gorjan Hrustanovic, PhD,
  • John Maraganore, PhD,
  • Leigh Morgan,
  • Victor Sandor, MDCM,
  • Elena Ridloff, CFA,

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Paltusotine

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing therapeutics for rare endocrine diseases and related tumors. Their leading product candidate, Paltusotine, has completed phase III trials for acromegaly treatment.

Tags: Paltusotine, biotechnology, clinical trials, endocrine diseases, pharmaceutical, therapeutics

Symbol: CRNX

Recent Price: $50.67

Industry: Biotechnology

CEO: Dr. R. Scott Struthers Ph.D.

Sector: Healthcare

Employees: 290

Address: Building No. 2, San Diego, CA 92121

Phone: 858 450 6464

Last updated: 2024-12-31

SCYNEXIS, Inc.

SCYNEXIS, Inc. logo
Market Cap: Lowest
Employees: Lowest

BREXAFEMME (ibrexafungerp tablets)

SCYNEXIS, Inc. is a biotechnology company focused on developing products for the treatment of fungal infections. They offer BREXAFEMME for the treatment of vulvovaginal candidiasis and are developing Ibrexafungerp, an oral and intravenous drug for various fungal infections.

Tags: BREXAFEMME, Biotechnology, Fungal Infections, Ibrexafungerp, Pharmaceuticals

Symbol: SCYX

Recent Price: $1.07

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. David Gonzalez Angulo M.D.

Sector: Healthcare

Employees: 29

Address: 1 Evertrust Plaza, Jersey City, NJ 07302-6548

Phone: 201 884 5485

Leadership

  • Armando Anido, Director
  • Steven C. Gilman, Ph.D., Director
  • David Angulo, M.D., President and Chief Executive Officer
  • Scott Sukenick, Chief Legal Officer
  • Ivor Macleod, MBA, CPA, Chief Financial Officer
  • Daniella Gigante, Vice President, Human Resources and Information Technology
  • Rossana Ferrara-Pontoriero, Ph.D., Vice President, Business Development and Alliance Management
  • Guy Macdonald, Chairman of the Board
  • Ann F. Hanham, Ph.D., Director
  • David Hastings, Director
  • Philippe Tinmouth, Director

Last updated: 2024-12-31

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

TERN-101, TERN-201, TERN-501, TERN-601

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.

Tags: NASH, biopharmaceutical, clinical trials, obesity, pharmaceutical research

Symbol: TERN

Recent Price: $7.15

Industry: Biotechnology

CEO: Ms. Amy L. Burroughs M.B.A.

Sector: Healthcare

Employees: 66

Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404

Phone: 650 525 5535

Last updated: 2024-11-08